Prevention and repair of circulatory shock and cerebral ischemia/injury by various agents in experimental heatstroke

Cheng Kuei Chang, Ching Ping Chang, Wen Ta Chiu, Mao Tsun Lin

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The current report summarized animal models of heatstroke experimentation that advance our current knowledge of therapeutic effects on cerebrovascular dysfunction, hypercoagulable state and/or systemic inflammation with various agents in the setting of heatstroke. This was a narrative review of selected published primary basic literature from MEDLINE for 1973-2006. It was found that rodents shared with humans almost the same heatstroke reactions such as hyperpyrexia, hypotension, hyperventilation, pulmonary edema, hepatic and renal failure, hypercoagulable state, metabolic acidosis, systemic inflammation, and cerebral ischemia, injury and dysfunction. Therefore, the rodent model would allow testing of new therapeutic strategies for heatstroke. It was found that brain cooling produced by infusion of cold (4°C) normal saline via the jugular vein or whole body cooling improved survival during heatstroke by reducing cerebrovascular dysfunction, multiple organ failure, systemic inflammation and hypercoagulable state. However, even under the absence of brain or whole body cooling, these heatstroke reactions still could be reversed by treating with the following agents: (1) free radical scavengers; (2) human recombinant protein C: (3) platonin; (4) hyperbaric oxygen; (5) hydroxyethyl starch, hypertonic solution, or human albumin; (6) glucocorticoids; (7) interleukin-1 receptor antagonists; (8) L-arginine; (9) estrogen; and (10) human umbilical cord blood cells or CD +34 cells. Before initiation of heat stress, prior manipulations with one of the following measures were found to be able to protect against heatstroke syndromes: (1) systemic delivery of inducible nitric oxide synthase inhibitors, mu-opioid receptor antagonists, endothelin-1A receptor antagonists, dopaminergic or serotoninergic nerve depletor or receptor antagonists, or glutamate receptor antagonists; or (2) heat shock protein 72 preconditioning.

Original languageEnglish
Pages (from-to)3145-3154
Number of pages10
JournalCurrent Medicinal Chemistry
Volume13
Issue number26
Publication statusPublished - Nov 2006

Fingerprint

Heat Stroke
Brain Ischemia
Shock
Repair
Cooling
Brain
Wounds and Injuries
HSP72 Heat-Shock Proteins
Hypertonic Solutions
Excitatory Amino Acid Antagonists
Free Radical Scavengers
Interleukin-1 Receptors
Narcotic Antagonists
Dopamine Antagonists
mu Opioid Receptor
Endothelins
Nitric Oxide Synthase Type II
Protein C
Recombinant Proteins
Starch

Keywords

  • CD+34 cells
  • Estrogen
  • Free radical scavengers
  • Glucocorticoids
  • Heatstroke
  • Human albumin
  • Human recombinant activated protein C
  • Hydroxyethyl starch
  • Hyperbaric oxygen
  • Interleukin-1 receptor antagonists
  • L-arginine
  • Platonin

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Prevention and repair of circulatory shock and cerebral ischemia/injury by various agents in experimental heatstroke. / Chang, Cheng Kuei; Chang, Ching Ping; Chiu, Wen Ta; Lin, Mao Tsun.

In: Current Medicinal Chemistry, Vol. 13, No. 26, 11.2006, p. 3145-3154.

Research output: Contribution to journalArticle

@article{3c5402f50dd84392812c2390985f1af8,
title = "Prevention and repair of circulatory shock and cerebral ischemia/injury by various agents in experimental heatstroke",
abstract = "The current report summarized animal models of heatstroke experimentation that advance our current knowledge of therapeutic effects on cerebrovascular dysfunction, hypercoagulable state and/or systemic inflammation with various agents in the setting of heatstroke. This was a narrative review of selected published primary basic literature from MEDLINE for 1973-2006. It was found that rodents shared with humans almost the same heatstroke reactions such as hyperpyrexia, hypotension, hyperventilation, pulmonary edema, hepatic and renal failure, hypercoagulable state, metabolic acidosis, systemic inflammation, and cerebral ischemia, injury and dysfunction. Therefore, the rodent model would allow testing of new therapeutic strategies for heatstroke. It was found that brain cooling produced by infusion of cold (4°C) normal saline via the jugular vein or whole body cooling improved survival during heatstroke by reducing cerebrovascular dysfunction, multiple organ failure, systemic inflammation and hypercoagulable state. However, even under the absence of brain or whole body cooling, these heatstroke reactions still could be reversed by treating with the following agents: (1) free radical scavengers; (2) human recombinant protein C: (3) platonin; (4) hyperbaric oxygen; (5) hydroxyethyl starch, hypertonic solution, or human albumin; (6) glucocorticoids; (7) interleukin-1 receptor antagonists; (8) L-arginine; (9) estrogen; and (10) human umbilical cord blood cells or CD +34 cells. Before initiation of heat stress, prior manipulations with one of the following measures were found to be able to protect against heatstroke syndromes: (1) systemic delivery of inducible nitric oxide synthase inhibitors, mu-opioid receptor antagonists, endothelin-1A receptor antagonists, dopaminergic or serotoninergic nerve depletor or receptor antagonists, or glutamate receptor antagonists; or (2) heat shock protein 72 preconditioning.",
keywords = "CD+34 cells, Estrogen, Free radical scavengers, Glucocorticoids, Heatstroke, Human albumin, Human recombinant activated protein C, Hydroxyethyl starch, Hyperbaric oxygen, Interleukin-1 receptor antagonists, L-arginine, Platonin",
author = "Chang, {Cheng Kuei} and Chang, {Ching Ping} and Chiu, {Wen Ta} and Lin, {Mao Tsun}",
year = "2006",
month = "11",
language = "English",
volume = "13",
pages = "3145--3154",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "26",

}

TY - JOUR

T1 - Prevention and repair of circulatory shock and cerebral ischemia/injury by various agents in experimental heatstroke

AU - Chang, Cheng Kuei

AU - Chang, Ching Ping

AU - Chiu, Wen Ta

AU - Lin, Mao Tsun

PY - 2006/11

Y1 - 2006/11

N2 - The current report summarized animal models of heatstroke experimentation that advance our current knowledge of therapeutic effects on cerebrovascular dysfunction, hypercoagulable state and/or systemic inflammation with various agents in the setting of heatstroke. This was a narrative review of selected published primary basic literature from MEDLINE for 1973-2006. It was found that rodents shared with humans almost the same heatstroke reactions such as hyperpyrexia, hypotension, hyperventilation, pulmonary edema, hepatic and renal failure, hypercoagulable state, metabolic acidosis, systemic inflammation, and cerebral ischemia, injury and dysfunction. Therefore, the rodent model would allow testing of new therapeutic strategies for heatstroke. It was found that brain cooling produced by infusion of cold (4°C) normal saline via the jugular vein or whole body cooling improved survival during heatstroke by reducing cerebrovascular dysfunction, multiple organ failure, systemic inflammation and hypercoagulable state. However, even under the absence of brain or whole body cooling, these heatstroke reactions still could be reversed by treating with the following agents: (1) free radical scavengers; (2) human recombinant protein C: (3) platonin; (4) hyperbaric oxygen; (5) hydroxyethyl starch, hypertonic solution, or human albumin; (6) glucocorticoids; (7) interleukin-1 receptor antagonists; (8) L-arginine; (9) estrogen; and (10) human umbilical cord blood cells or CD +34 cells. Before initiation of heat stress, prior manipulations with one of the following measures were found to be able to protect against heatstroke syndromes: (1) systemic delivery of inducible nitric oxide synthase inhibitors, mu-opioid receptor antagonists, endothelin-1A receptor antagonists, dopaminergic or serotoninergic nerve depletor or receptor antagonists, or glutamate receptor antagonists; or (2) heat shock protein 72 preconditioning.

AB - The current report summarized animal models of heatstroke experimentation that advance our current knowledge of therapeutic effects on cerebrovascular dysfunction, hypercoagulable state and/or systemic inflammation with various agents in the setting of heatstroke. This was a narrative review of selected published primary basic literature from MEDLINE for 1973-2006. It was found that rodents shared with humans almost the same heatstroke reactions such as hyperpyrexia, hypotension, hyperventilation, pulmonary edema, hepatic and renal failure, hypercoagulable state, metabolic acidosis, systemic inflammation, and cerebral ischemia, injury and dysfunction. Therefore, the rodent model would allow testing of new therapeutic strategies for heatstroke. It was found that brain cooling produced by infusion of cold (4°C) normal saline via the jugular vein or whole body cooling improved survival during heatstroke by reducing cerebrovascular dysfunction, multiple organ failure, systemic inflammation and hypercoagulable state. However, even under the absence of brain or whole body cooling, these heatstroke reactions still could be reversed by treating with the following agents: (1) free radical scavengers; (2) human recombinant protein C: (3) platonin; (4) hyperbaric oxygen; (5) hydroxyethyl starch, hypertonic solution, or human albumin; (6) glucocorticoids; (7) interleukin-1 receptor antagonists; (8) L-arginine; (9) estrogen; and (10) human umbilical cord blood cells or CD +34 cells. Before initiation of heat stress, prior manipulations with one of the following measures were found to be able to protect against heatstroke syndromes: (1) systemic delivery of inducible nitric oxide synthase inhibitors, mu-opioid receptor antagonists, endothelin-1A receptor antagonists, dopaminergic or serotoninergic nerve depletor or receptor antagonists, or glutamate receptor antagonists; or (2) heat shock protein 72 preconditioning.

KW - CD+34 cells

KW - Estrogen

KW - Free radical scavengers

KW - Glucocorticoids

KW - Heatstroke

KW - Human albumin

KW - Human recombinant activated protein C

KW - Hydroxyethyl starch

KW - Hyperbaric oxygen

KW - Interleukin-1 receptor antagonists

KW - L-arginine

KW - Platonin

UR - http://www.scopus.com/inward/record.url?scp=33750578847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750578847&partnerID=8YFLogxK

M3 - Article

C2 - 17168703

AN - SCOPUS:33750578847

VL - 13

SP - 3145

EP - 3154

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 26

ER -